| Literature DB >> 22419043 |
Abstract
Diabetic nephropathy is the leading cause of end-stage renal disease in the United States. Renin-angiotensin-aldosterone system (RAAS) blockers are thought to have a specific renoprotective effect in diabetes. Hirst et al. report the results of randomized clinical trials assessing the effects of RAAS inhibitors on urinary albumin excretion levels in diabetic patients. Although reductions in urinary albumin excretion were observed, whether RAAS inhibitors offer additional protection over other antihypertensive agents is unclear.Entities:
Mesh:
Year: 2012 PMID: 22419043 DOI: 10.1038/ki.2011.460
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612